Dr. Blake A. Jones, MD
Gastroenterology (Gastroenterology Physician)
2820 Mount Rushmore Rd
Rapid City, SD 57701
Who else practices at this address →
Pennington County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 578
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
SD license 8918
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Monument Health Rapid City Hospital Rapid City, SD
- Monument Health Custer Hospital Custer, SD
- Black Hills Surgical Hospital LLC Rapid City, SD
Medical groups
- Black Hills Surgical Hospital LLC (174 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 578
- Services billed
- 2,358
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 226 | 224 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 174 | 169 |
| Biopsy of large bowel using a flexible endoscope | 89 | 88 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 69 | 69 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 59 | 58 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 55 | 25 |
| Blood test, comprehensive group of blood chemicals | 35 | 21 |
| Insertion of needle into vein for collection of blood sample | 35 | 30 |
| Injection beneath lining of large bowel using a flexible endoscope | 34 | 33 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Rapid City, SD | 268 |
| Ondansetron Hcl Other prescribers in Rapid City, SD | 267 |
| Omeprazole Other prescribers in Rapid City, SD | 138 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Rapid City, SD | 110 |
| Gavilyte-C (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Rapid City, SD | 73 |
| Budesonide Dr (budesonide) Other prescribers in Rapid City, SD | 33 |
| Mesalamine Other prescribers in Rapid City, SD | 19 |
| Ursodiol Other prescribers in Rapid City, SD | 17 |
| Pantoprazole Sodium Other prescribers in Rapid City, SD | 17 |
| Prednisone Other prescribers in Rapid City, SD | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 8 payments worth $341 in total to this clinician.
| Janssen Biotech, Inc. | $253 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $71.73 |
| AbbVie Inc. | $16.05 |
| Food and Beverage | $341 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $101,317 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - Entyvio (vedolizumab) long-term safety study: an international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or crohn's disease
Takeda Pharmaceuticals U.S.A., Inc. - A study of TAK-062 in treatment of active celiac disease in participants attempting a gluten-free diet
Takeda Pharmaceuticals U.S.A., Inc. - A phase 4 study evaluating real-world use of cdpath?, a crohn's disease risk prediction tool
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.